#plinazolin-group-30 tag

Cancer

Here are the top locations for cancer research in the Nature Index

Medicine

The very long road from a cancer cure' in mice to one in humans

Here are the top locations for cancer research in the Nature Index

Breast cancer leads in research output, significantly ahead of lung cancer and other types, with the US and China contributing 60% of global cancer research.

Medicine

The very long road from a cancer cure' in mice to one in humans

Cancer

New Drug Doubles One-Year Survival in Pancreatic Cancer Trial - News Center

fromwww.independent.co.uk

Science

The true story behind Mariano Barbacid's first effective therapy against pancreatic cancer'

Cancer

Scientists may have found key to treating hidden cancer growths

fromNews Center

New Drug Doubles One-Year Survival in Pancreatic Cancer Trial - News Center

Elraglusib combined with chemotherapy reduces the risk of death in pancreatic cancer patients by 38% and improves one-year survival rates.

fromwww.independent.co.uk

Science

The true story behind Mariano Barbacid's first effective therapy against pancreatic cancer'

Cancer

Scientists may have found key to treating hidden cancer growths

more#pancreatic-cancer

from24/7 Wall St.

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

Lilly's fourth quarter revenue reached $19.29 billion, up 42.6% year-over-year, powered almost entirely by two products. Mounjaro generated $7.41 billion, up 110%, while Zepbound added $4.26 billion, up 123%.

Medicine

fromwww.theguardian.com

GSK reports promising early results in ovarian and womb cancer drug trial

GSK's Mo-Rez treatment shows promising results in shrinking tumors for ovarian and endometrial cancers, leading to plans for late-stage trials.

fromwww.theguardian.com

Repurposed drug may extend survival in aggressive ovarian cancer, trial shows

The study published in the Lancet analyzed data from 381 patients with platinum-resistant ovarian cancer, revealing a 35% reduction in the risk of death among those treated with relacorilant compared to usual care.

Cancer

from24/7 Wall St.

2 weeks ago

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution is driving biopharma M&A strategies, with companies like Viking Therapeutics and Structure Therapeutics as prime acquisition targets.

2 weeks ago

New drugs take aim at one of cancer's deadliest mutations

Researchers are developing innovative strategies to target the cancer-causing KRAS protein, previously deemed 'undruggable', showing promising results in clinical trials.

fromBusiness Matters

4 weeks ago

Dr. Chengzao Sun: Building the Future of Peptide Drugs

Peptide drugs are rapidly advancing in biotech, driven by scientists like Dr. Chengzao Sun, who focus on solving complex problems.

fromScienceDaily

What happens after Ozempic shocked researchers

Stopping GLP-1 medications like Ozempic does not typically lead to significant weight regain, as many patients switch treatments or restart therapy.

from24/7 Wall St.

uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts

RBC Capital analyst Luca Issi upgraded the stock to Outperform from Sector Perform with a price target of $35, up from $11. Wells Fargo also upgraded uniQure to Overweight from Equal Weight with a $60 price target. The catalyst: the departure of Vinay Prasad from the FDA. RBC views this as a positive for uniQure, noting it is "not inconceivable" that the FDA reverts to its prior stance, and believes Prasad's departure is likely to open up a more balanced discussion on risk/reward for Huntington's disease.

NYC startup

fromTNW | Health-Tech

Kupando raises 10M more to take its immunity drug into the clinic

Kupando raised €10 million in Series A extension funding to advance KUP101, a dual TLR agonist, toward first human trials for solid tumors and drug-resistant infections.

Public health

Six highlights from lung-health research

AI models combining sensor, satellite, traffic, and weather data can substantially improve air-quality forecasting and warnings but face data, transferability, interpretability, and energy-cost limitations.

fromwww.bbc.com

Proton beam hope for asbestos cancer patients

A proton beam trial offers realistic hope for mesothelioma patients by delivering high-dose radiation precisely to affected areas, potentially increasing two-year survival rates from 30% to 50%.

fromBusiness Matters

Flavia Pichiorri: Turning Cancer Research Into Real Therapies

Dr. Flavia Pichiorri bridges laboratory discoveries and clinical applications in blood cancer research, focusing on therapeutic targets and radiation strategies to accelerate patient treatment outcomes.

A living drug manages to eliminate tumors in mice with pancreatic, ovarian and kidney cancer

An ultrasensitive CAR-T cell therapy successfully eliminated solid tumors in laboratory mice by targeting the CD70 protein at previously undetectable levels.

fromNews Center

Combination Treatment May Slow Disease Progression in Advanced Sarcoma - News Center

Cabozantinib plus temozolomide, given orally, showed potential to slow progression of advanced leiomyosarcoma and merits further clinical evaluation.

fromwww.bbc.com

'Weight-loss jab helped me find my cancer'

The cancer was fastacting, and if I'd left it even six months, the outcome could have been much worse,

Medicine

Treatments for idiopathic pulmonary fibrosis are on the horizon

Idiopathic pulmonary fibrosis causes progressive lung scarring leading to respiratory failure within three to five years; current drugs slow decline but do not lower mortality.

fromSilicon Canals